Lobucavir API is a synthetic carbocyclic nucleoside analogue structurally related to guanine and was developed as a broad-spectrum antiviral compound. Also known by development codes including BMS-180194 and Cyclobut-G, Lobucavir has been investigated for antiviral activity against a range of DNA viruses, including cytomegalovirus (CMV), herpesviruses and hepatitis B virus (HBV). Its antiviral activity is associated with intracellular phosphorylation to active nucleotide metabolites that interfere with viral DNA polymerase and viral DNA synthesis.
Lobucavir is chemically identified as 2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-1H-purin-6-one. The compound has the molecular formula C₁₁H₁₅N₅O₃, molecular weight approximately 265.27 g/mol, and CAS No. 127759-89-1. It contains three defined stereocenters and is represented as a specific stereochemical form rather than a simple unspecified mixture.
Lobucavir was investigated clinically for hepatitis B, herpes simplex virus infections and cytomegalovirus infections. Although it demonstrated antiviral activity and progressed into clinical development, its development was discontinued following findings from long-term animal studies that raised concerns regarding carcinogenic risk. Accordingly, Lobucavir should be described as an investigational compound rather than as an approved marketed pharmaceutical API.
The compound is relevant to pharmaceutical research involving viral DNA polymerase inhibition, nucleoside analogue development, antiviral drug discovery, virology, medicinal chemistry and analytical research. It may also be used as a research or reference material where appropriately characterized material is required.
MEDIOCON INC supplies Lobucavir for pharmaceutical research, analytical applications, drug-development programs and applicable research-material requirements, subject to product availability, applicable specifications, regulatory requirements and supporting documentation. The exact material grade, purity, stereochemical identity, analytical profile, packaging and documentation should be confirmed against the applicable Certificate of Analysis before use.
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Lobucavir API Manufacturer & Supplier in India | MEDIOCON INC (CAS 127759-89-1) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Lobucavir API Manufacturer & Supplier in India | MEDIOCON INC is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.
Export Markets
Quality & Compliance